Foundations Investment Advisors LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD

Foundations Investment Advisors LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 26.4% in the 2nd quarter, HoldingsChannel reports. The firm owned 82,876 shares of the biopharmaceutical company’s stock after acquiring an additional 17,318 shares during the quarter. Foundations Investment Advisors LLC’s holdings in Gilead Sciences were worth $9,188,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in GILD. Activest Wealth Management grew its position in Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the period. GoalVest Advisory LLC raised its position in Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the period. Harbor Asset Planning Inc. purchased a new position in Gilead Sciences in the second quarter valued at about $27,000. Putney Financial Group LLC grew its position in shares of Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares during the period. Finally, Colonial Trust Advisors grew its position in shares of Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 213 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Insider Activity

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total value of $1,193,900.00. Following the sale, the chief executive officer owned 581,203 shares in the company, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the transaction, the insider owned 113,193 shares of the company’s stock, valued at approximately $12,855,329.01. The trade was a 2.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 94,646 shares of company stock valued at $11,311,286 in the last quarter. 0.27% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently commented on GILD shares. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Gilead Sciences in a report on Monday, November 3rd. UBS Group boosted their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. Truist Financial reaffirmed a “buy” rating and set a $145.00 price target (up previously from $127.00) on shares of Gilead Sciences in a research report on Monday, November 3rd. Wolfe Research increased their price target on Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a research note on Thursday, October 23rd. Finally, Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a research note on Friday, September 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $129.13.

Gilead Sciences Stock Down 0.1%

Shares of NASDAQ GILD opened at $125.02 on Friday. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The company has a market cap of $155.11 billion, a P/E ratio of 24.90, a P/E/G ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a 52 week low of $86.08 and a 52 week high of $127.68. The business has a 50-day simple moving average of $117.44 and a two-hundred day simple moving average of $112.83.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the prior year, the business posted $2.02 earnings per share. The company’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.